Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test
Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment. Moderna and Merck are developing an mRNA-based cancer vaccine designed to be tailored to individual patients based on unique mutations within their tumors.